One report predicts six late-stage development drugs will be launched during this period.
According to GlobalData, the glaucoma market across seven major markets (7MM) is expected to reach US$250 million by 2033, growing at a CAGR of 2.1%.
The industry's expansion has been attributed to the aging population leading to increased disease in this patient population and the introduction of pipeline products.
The report predicts the launch of six late-stage drugs during this period, including prostaglandin analogs, intracameral implants and therapies with novel mechanisms of action.
“However, the crowded and highly generic glaucoma market means competition for new treatments is fierce,” said Shireen Mohammad, senior cardiovascular and metabolic disease analyst at GlobalData.
Meanwhile, key opinion leaders (KOLs) and prescribers identify poor patient compliance as a major unmet need.
There is also a market need for treatments with enhanced intraocular pressure (IOP) lowering capabilities, neuroprotective properties, and advances in disease diagnosis and monitoring.
Mohammad added: “KOLs have expressed enthusiasm for this shift, emphasizing the increasing need to optimize the delivery of existing treatments rather than focusing solely on creating new treatments that go beyond lowering IOP.”
7MM = United States, France, Germany, Italy, Spain, United Kingdom and Japan
